

Document downloaded from:

<http://hdl.handle.net/10251/80507>

This paper must be cited as:

Jiménez Belenguer, AI.; Doménech Antich, EM.; Fenollar-Penadés, A.; Ferrús Pérez, MA. (2016). Antimicrobial Resistance of *Escherichia coli* isolated in newborn chickens and effect of amoxicillin treatment during its growth. *Avian Pathology*. 45(4):501-507.  
doi:10.1080/03079457.2016.1168515.



The final publication is available at

<http://dx.doi.org/10.1080/03079457.2016.1168515>

Copyright Taylor & Francis

Additional Information

1 **Antimicrobial Resistance of *Escherichia coli* isolated in one day old**  
2 **chickens and effect of amoxicillin treatment during its growth**

3

4 **Ana Jiménez-Belenguer (Corresponding author)**

5 *Affiliation: Biotechnology Department. Centro Avanzado de Microbiología de*  
6 *Alimentos. Universitat Politècnica de València. Camino de Vera 14, P.O. Box 46022,*  
7 *Valencia, Spain. Tel.: +34 963877423; fax: +34 963877429*

8 *E-mail address: [anjibe@upvnet.upv.es](mailto:anjibe@upvnet.upv.es)*

9 **Eva Doménech**

10 *Affiliation: Institute of Food Engineering for Development (IUIAD), Food*  
11 *Technology Department (DTA), Universitat Politècnica de Valencia. Camino de Vera*  
12 *14, P.O. Box 46022 Valencia, Spain*

13 *E-mail address: [evdoan@tal.upv.es](mailto:evdoan@tal.upv.es)*

14 **Arantxa Villagrà**

15 *Affiliation: Centro de Tecnología Animal CITA-IVIA. Polígono La Esperanza nº 100,*  
16 *P.O. Box 12400 Segorbe, Castellon, Spain*

17 *Telf: +34964712566*

18 *E-mail address: [Villagra\\_ara@gva.es](mailto:Villagra_ara@gva.es)*

19 **Alejandro Fenollar**

20 *Affiliation: Biotechnology Department. Universitat Politècnica de València. Camino*  
21 *de Vera 14, P.O. Box 46022, Valencia, Spain*

22 *E-mail address: [alfepe@etsiamn.upv.es](mailto:alfepe@etsiamn.upv.es)*

23 **Maria Antonia Ferrús**

24 *Affiliation: Biotechnology Department. Centro Avanzado de Microbiología de*

25 *Alimentos Universitat Politècnica de València. Camino de Vera 14, P.O. Box 46022,*

26 *Valencia, Spain*

27 *E-mail address: [mferrus@btc.upv.es](mailto:mferrus@btc.upv.es)*

28

29 **Antimicrobial Resistance of *Escherichia coli* isolated in one day old**  
30 **chickens and effect of amoxicillin treatment during its growth**

31

32 **Abstract**

33

34 The use of antimicrobials in food animals is the major determinant for the propagation of  
35 resistant bacteria in the animal reservoir. However, other factors also play a part. In particular,  
36 vertical spread between the generations has been suggested to be an important transmission  
37 pathway. The objective of this paper was to determine the resistance patterns of *E. coli* isolated  
38 from farmed newborn chickens as well as to study the antibiotic pressure effect when  
39 amoxicillin was administered during their growing period. With this aim, meconium from 22  
40 one day old Ross chickens was analyzed. In addition, during their growth period, amoxicillin  
41 treatments on days 7, 21 and 35 were carried out. Results showed a high number of *E.coli*  
42 resistant strains isolated from one day chickens, being the highest rates for beta-lactams group,  
43 followed by quinolone and tetracyclines. Moreover, as expected, analysis during the productive  
44 cycle of chickens after treatment with amoxicillin showed that the highest percentage of  
45 resistances were detected for this antibiotic. Moreover, significant differences in resistance  
46 percentages between control and treated broilers were detected in relation to ampicillin,  
47 cephalothin streptomycin, kanamycin, gentamicin, chloramphenicol and tetracycline.  
48 Differences in resistances to ciprofloxacin and nalidixic acid between control and treated  
49 animals were not observed. Finally, no resistance was detected for amikacin and ceftriaxone.  
50 These results suggest the possibility of vertical transmission of resistant strains to newborn  
51 chickens from parenteral flocks, and seem to indicate that the treatment with amoxicillin had a  
52 cross effect, increasing the resistances of *E. coli* to other antibiotics.

53

54 **Key words:** Newborn chickens, antimicrobial resistance, vertical transmission, *E. coli*.

55

56 **1. Introduction**

57

58 Antimicrobial resistance is a main concern, since resistant bacteria can pose a greater  
59 risk to human health as a result of potential treatment failure, loss of treatment options  
60 and increased likelihood and severity of disease. In fact, treatment failures by  
61 multiresistant strains are responsible for half of the approximately 27,000 annual deaths  
62 from infections in the European Union (Watson, 2008).

63 The use of antimicrobials drugs to treat and prevent diseases in animals or to  
64 promote their growth has been accompanied by the development of antimicrobial  
65 resistances. Transmission of resistance from animals to humans can take place through a  
66 variety of routes, where the food-borne route probably is the most important. Reduction  
67 in the use of antimicrobial agents can have a positive effect on the occurrence of  
68 antimicrobial resistance in humans and nowadays, the use of sub-therapeutic doses in  
69 order to increase the body weight is completely banned in the European Union since  
70 January 2006 (Regulation 1831/2003/EC).

71 Resistant strains selected by animal antimicrobial treatments can reach humans via  
72 other animals, sewage, or other humans, such as farmers or slaughterers (Phillips et al.,  
73 2003, Miranda, et al., 2007). Thus, transmission of resistant isolates between animals  
74 and environment makes necessary go ahead and invest in preventive measures. In this  
75 sense, addressing zoonotic transmission of pathogens that are resistant to antimicrobials  
76 is crucial to stablish effectice risk management policies.

77 Amoxicillin (AMX) is a broad spectrum  $\beta$ -lactam penicillin, introduced in human  
78 medicine in the early 1970s and used for the treatment of infections caused by Gram  
79 negative and positive bacteria. In fact, AMX is recommended by the European  
80 guidelines as the first-choice antibiotic for treating mild respiratory and other common

81 infections in non-hospitalized patients. For all these reasons, when investigating  
82 resistance spreading among farm animals, amoxicillin is one of the most interesting  
83 antibiotics to study.

84 On the other hand, poultry was the most dynamic meat sector during the last decade.  
85 In fact, the total poultry meat production increased from 69 million tons in 2000 to 94  
86 million tons in 2008, which corresponds to an increase of 35% (FAO, 2010). Nowadays,  
87 this kind of meat represents 30% of the global meat consumption and chickens,  
88 followed by far for turkeys, are the most common sources of poultry meat (87% and  
89 6.7%, respectively) (FAO, 2010).

90 Surveillance of resistance in commensal bacteria is important because they can be  
91 reservoirs of resistance determinants and because they are more ubiquitous than  
92 pathogens. Exchange of resistance genes occurs between pathogens and nonpathogens,  
93 even between gram-positive and gram-negative organisms. Of particular interest are  
94 enterococci and *E. coli*, that can play a role in transmission of mobile resistance genes  
95 (McEwen and Fedorka-Cray, 2002). *E. coli* isolated in healthy animals, carcasses or  
96 meat thereof, provides valuable data for investigating relationship with the selective  
97 pressure exerted by the use of antimicrobials on the intestinal population of bacteria in  
98 food-producing animals and determining the occurrence of resistance to antimicrobials.  
99 *E. coli* is also useful as representative of *Enterobacteriaceae* to monitor the emergence  
100 and changes in the proportion of bacteria possessing ESBL (EFSA 2013).

101 Therefore, the objective of this paper was to determine the antibiotic resistances  
102 pattern of *E. coli* in newborn chicken, in order to assess the possibility of vertical  
103 transmission from parenteral flocks, and to study the antibiotic pressure effect that the  
104 administration of amoxicillin through their growth has in the development of  
105 antimicrobial resistance rates in their comensal gut microbiota.

106

## 107 **2. Materials and methods**

108

### 109 *2.1. Breeding chickens*

110 A total of one day old 22 healthy Ross male chickens were obtained from the same  
111 commercial hatchery. Reception of chickens was carried out in the “Centro de  
112 Investigación Tecnológica Animal” in Segorbe, Castellón (Spain). Chickens were  
113 labeled and randomly assigned to six groups of three chickens and one with four chicks.  
114 Each group was conducted separately and between-group transmission was avoided by  
115 having a solid separation between pens. All the pens had a trough and three water nipple  
116 dispensers and the floor was covered with 10 cm of wood shavings. The chickens were  
117 fed with the same free-antimicrobial feed. All parts of this study were carried out  
118 according to EC council directives (2010/63/EU) concerning the laws, regulations, and  
119 administrative provisions of the member states regarding the protection of animals used  
120 for experimental and other scientific purposes (2015/VSC/PEA/00178).

121

### 122 *2.2. Antibiotic administration*

123 One of the groups (the one with four chicks) was considered the control and was kept  
124 untreated. The six remaining groups were treated with amoxicillin (Neudiaval oral  
125 powder (50x118 g Laboratory Mevet, Lérida, Spain) according to manufacturer’s  
126 instructions. Chickens were kept in the experimental facilities from day of arrival (day  
127 0) until day of slaughter (day 49) and they were weighed and treated with different  
128 doses of amoxicillin: D1, 24 mg amoxicillin/kg of animal; D2, 12 mg amoxicillin/kg of  
129 animal and D3, 8 mg amoxicillin/kg of animal. Each dose was administered to two  
130 different groups. Dose administration was carried out with an oral syringe. The

131 treatments (T) were administered over 3 days. The treatment one (T1) started in day 7,  
132 treatment two (T2) day 21 and treatment three (T3) day 35 of chickens life cycle. No  
133 other antimicrobial treatment was administered during the course of the experiment.

134

### 135 2.3. *Sample collection*

136 Four sample collections were carried out during the experimental period,  
137 immediately before administration of antibiotic doses. First sampling was on day 0 on  
138 meconia. Second and third samplings took place on days 21 and 35. Samples were taken  
139 directly from the cloaca using a sampling swab (Deltalab Collection and transport  
140 system. Amies swab ps+viscose). The final sampling was on day 49 and samples were  
141 taken directly from the cecum after slaughtering all the animals with over-doses with  
142 embutramide. In all cases, the samples were refrigerated until they were processed in  
143 the laboratory.

144

### 145 2.4. *Escherichia coli isolation*

146 TBX agar plates (T.B.X. Medium, OXOID Ltd., England, UK) were inoculated and  
147 incubated at 44°C for 24h. Two randomized colonies of each plate were isolated,  
148 transferred to PC agar (Plate Count Agar, Scharlau, Barcelona, Spain) and incubated to  
149 37°C for 24h. The isolates from the PC agar plates were then checked as *E. coli* with the  
150 API-20 E system (Biomérieux, France). Colonies identified as *E. coli* were selected for  
151 the antibiogram test.

152

### 153 2.5. *Antimicrobial susceptibility*

154 Antimicrobial susceptibility determination of isolated *E. coli* was completed by a  
155 standard disc diffusion assay (Antimicrobial Susceptibility Test Disc, OXOID Ltd.,



156 England, UK) on Mueller Hinton agar (BBL™ Mueller-Hinton II Agar, BD). The MIC  
157 breakpoints and levels of resistance were determined according to the recommendations  
158 of the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS, 2002). The *E.*  
159 *coli* strains were tested against 12 antibiotics of veterinary and sanitary significance:  
160 gentamycin (CN) 10µg, amoxicillin/clavulamic acid (AMC) 3µg, ampicillin (AMP)  
161 10µg, amikacin (AK) 30µg, kanamycin (K) 30µg, cloranphenicol (C) 30µg, cephalothin  
162 (KF) 30µg, ciprofloxacin (CIP) 5µg, ceftriaxone (CRO) 30µg, tetracycline (TE) 30µg,  
163 nalidixic acid (NA) 30µg and streptomycin (S) 10µg.

164

## 165 2.6. Statistical analysis

166 Statistical analyses of the data were undertaken using Statgraphics Centurion XVI.II  
167 (Statpoint Technologies, Inc. Warrenton, Virginia). The possible relationship between  
168 treatments with amoxicillin and the increase of *E. coli* resistance to different groups of  
169 antibiotics were carried out with a Multiple Correspondence Analysis (MCA)  
170 (Greenacre, 2007). In MCA, subjects (rows) and variables (columns) can be depicted  
171 simultaneously on a graphical display; where a close position between different points  
172 indicates a relatively high level of association. On the contrary, when the points are in  
173 different parts of the axis, the association is low. Relative proportions were compared  
174 using the Chisquared test ( $X^2$ ) and Fisher's exact test. Comparisons of means were also  
175 performed. A probability value of less than 5% was deemed to be significant.

176

## 177 3. Results and discussion

178

### 179 3.1. Resistances found in in one-day-old chickens

180 *E. coli* strains isolated from one-day-old chicks' meconium showed resistance in  
181 63.3% (14 out of 22) and multiresistance, defined as resistance to at least three different  
182 antimicrobial classes, was observed in 95% (13 out of 14 meconia). The highest  
183 percentage of resistance was found against nalidixic acid (80%), ampicillin, and  
184 amoxicillin/clavulanic, both of them in 70% of samples, followed by tetracycline (30%)  
185 cephalothin (23.3%) and ciprofloxacin (16.7%). Lower than 10% resistances were  
186 found against streptomycin, gentamicin and kanamycin. Finally, none of the *E. coli*  
187 isolates was resistant to amikacin, chloramphenicol and ceftriaxone (Figure 1). Similar  
188 results were found by Martins da Costa et al. (2011) who found no *E. coli* resistant to  
189 chloramphenicol but observed resistant strains from one day-old-chicks against  
190 ampicillin, cephalothin, tetracycline, streptomycin, gentamicin and enrofloxacin. As this  
191 study was performed from chickens that had not been exposed to antimicrobial agents  
192 previously, a vertical transmission of resistant strains from parental flocks (Giovanardi  
193 et al., 2005a; 2005b) or by contamination in the hatchery environment (Dierikx et al.,  
194 2013) could be the main causes. In our work, environmental exposition to antibiotics  
195 was limited by the conditions of experimental design: "Centro de Investigación  
196 Tecnológica Animal" is not a conventional, but an experimental farm, in which  
197 chickens were maintained into high hygienic pens, thus reducing as much as possible  
198 the spreading of antibiotic exposure through environment. Thus, contamination of  
199 chickens via vertical transmission seems to be the most probable explanation to the high  
200 resistance rates found.

201 According to Petersen et al. (2006) parents represent an extensive bacterial reservoir  
202 from which transmission may occur through contamination of the eggs shell during lay.  
203 The study performed by Bortolaia et al. (2010) was also consistent with vertical  
204 transmission of ampicillin and nalidixic acid resistant *E. coli* through the broiler

205 production system. These authors concluded that clones among parent and broiler flocks  
206 were indistinguishable, which indicated that transmission of ampicillin and nalidixic  
207 resistant *E. coli* occurred from parents to broilers. Bortolaia et al (2010) suggested,  
208 according to their findings, that resistance to beta-lactams and fluoro-quinolone in *E.*  
209 *coli* was due to vertical transmission through parent chickens. In the same framework,  
210 Baron et al. (2014) suggested that *E. coli* resistance may be introduced in the hatchery  
211 facilities, either form true vertical transmission when parental poultry stocks are  
212 contaminated or form very early contamination in the hatchery itself, or during  
213 transport, which is a period when the immature digestive flora is probably very  
214 receptive to early colonization, although other possible contamination events occurring  
215 thereafter on the production farm cannot be excluded.

216

### 217 3.2. Resistances patterns changes during experimental treatments with amoxicillin

218 During the growth period, three amoxicillin treatments were administrated. Results  
219 of resistant *E. coli* isolated strains showed no significant differences between them (p-  
220 value 0,1760), however, significant differences were found between isolates from  
221 control and treated broilers (p-value 0,0013). Finally, no significant differences existed  
222 in the resistances found between the three doses administrated (p-value 0.9025),  
223 consequently, values from the three doses were managed together.

224 Figure 2 shows the Multiple Correspondence Analysis (MCA) carried out to evaluate  
225 the global effect of each amoxicillin treatments on the profile of *E. coli* response  
226 (sensitive, intermediate and resistant) to different groups of antibiotics used. Two  
227 dimensional MCA solution accounts for 23.6% of the inertia (the first dimension  
228 accounts for 15.1% and the second 8.5%). Considering the x-axis, resistance and  
229 intermediate resistance of *E. coli* to antibiotics were located on the left; however,

230 antibiotic sensitivity was located on the right. Moreover, considering that the closer  
231 position the closer relationship, results showed that control samples had a higher  
232 percentage of *E. coli* strains sensitive to antibiotics and those obtained from chicken  
233 treated had a higher percentage of resistances. In addition, the antibiotics more related  
234 with resistance response were ampicillin, amoxicillin, cephalothin, which means that  
235 although only one antibiotic was used, it could be influencing other  $\beta$  lactam antibiotics.  
236 On the other hand of the axis, corresponding to antimicrobial sensitive response,  
237 ceftriaxone, kanamicin, gentamicin, ciprofloxacin and chloranphenicol presented a near  
238 position and consequently a high antimicrobial sensitivity. Considering the y-axis,  
239 fewer differences can be observed. However, the high distance of intermediate response  
240 indicates a low percentage of intermediate resistance.

241 Figure 3 shows the relationship between broiler chickens treatment with amoxicillin  
242 and antimicrobial resistance of *E. coli* to beta-lactams (amoxicillin, ampicillin,  
243 ceftriaxone and cephalothin); aminoglycosides (amikacin, gentamicyn, kanamycin and  
244 streptomycin); phenicol (chloranphenicol); quinolones (ciprofloxacin and nalidixic acid)  
245 and tetracycline (tetracycline).

246 Results showed that no animal (control and treated) presented *E. coli* strains resistant  
247 to amikacin and ceftriaxone. Similar results were found by Saenz et al. (2001) and  
248 Bywater et al. (2004). Taking into account the critical importance for human medicine  
249 of ceftriaxone (WHO, 2012; Domenech et al., 2015) the obtained results are  
250 encouraging.

251 Slight differences in resistances between control and treated flocks were found for  
252 ciprofloxacin and nalidixic acid. In addition, antimicrobial resistance in control birds  
253 (not exposed to antimicrobials) exhibited interesting changes over time in ciprofloxacin.  
254 In this cases, no resistant strains are present in control 1 (C1), corresponding to day 7 of

255 life cycle, however they appear in controls 2 and 3. In a previous study, Apajalahti et  
256 al., (2004), reported that microbial composition of the chicken gut can change according  
257 to the diet and the environment, directly by providing a continuous source of bacteria,  
258 or indirectly by influencing bird defense mechanisms. In general, a large numbers of  
259 chicks bearing resistant *E. coli* strains shed huge numbers of resistant isolates, resulting  
260 in rapid contamination of the other individuals in the same flock and production barn  
261 environment. This high level of contamination is probably difficult to eliminate even  
262 with strict disinfection procedures, particularly on farms with outdoor runs (Baron et al.,  
263 2014).

264 In this work, obtained values for resistance to nalidixic acid in treated chickens were  
265  $64\pm 8.2\%$  . The resistance rates of *E. coli* reported by EFSA, (2013) vary considerably  
266 between countries, from 0.6%, (n= 316) in Finland to 85.1% (n= 101 samples) in Spain.  
267 In relation to ciprofloxacin, obtained values were  $16.1\pm 4.8\%$ . These values are higher  
268 than those reported in Denmark 9% ( n=134 samples), and lower that the European  
269 mean 53.1 % (n=1703) (EFSA, 2013).

270 On the other hand, resistant *E. coli* to ampicillin, cephalothin, all aminoglycosides  
271 studied, chloramphenicol and tetracycline showed high differences between treated and  
272 no treated flocks. Moreover, only treated animals presented resistance to gentamicin,  
273 kanamycin streptomycin and chloramphenicol. When an antibiotic pressure is acting,  
274 those genes that are capable to permit the survival of the strains are selected. These  
275 selected genes can be horizontally transferred between different bacterial species (Van  
276 den Bogaard et al., 2001). Horizontal gene transfer is the most characteristic acquisition  
277 of resistance genes (Binnewies et al. 2006). Plasmids carrying genetic determinants  
278 which confer resistance to different classes of antibiotics confer a selective advantage  
279 for the carrier strains. This kind of plasmids are large, self-conjugative and control their

280 copy number by regulation of the replication rate in the cell (Nordstrom, 2005), what  
281 could lead to their persistence and spread in the microbial community of the intestine.  
282 Moreover, a study carried by Miller et al. (2004) showed that the exposure to beta-  
283 lactams induce the *dpiBA* operon, which inhibits the replication of the bacterial  
284 chromosome, inducing the SOS response and induce an enhancement of the genetic  
285 variability. These facts could explain the general higher rates of resistance for the  
286 treated group versus the control group.

287 The higher resistance rates for tetracyclines determined in this work was 67.6%,  
288 although the mean value was 37.4%. These values were relatively low as compared with  
289 a 75% of resistance reported by Sáenz et al., (2001) and was around the European mean  
290 value reported by EFSA, 2013 45.2% (n=2019). Multiresistant strains were more  
291 prevalent in each successive trial. This might be explained by the persistence of farm  
292 indigenous *E. coli* strains that were repeatedly exposed to antimicrobials (Furtula et al.,  
293 2010; Smith et al., 2007).

294 With regard to public health, amoxicillin, ampicillin, and nalidixic acid are on the list  
295 of Critically Important Antimicrobials published by the WHO Advisory Group on  
296 Integrated Surveillance of Antimicrobial Resistance (WHO, 2012), by accomplishing the  
297 criterion 1 (the antimicrobial agent is the sole, or one of limited available therapy, to  
298 treat serious human disease) and also the criterion 2 (Antimicrobial agent is used to treat  
299 diseases caused by either: (a) organisms that may be transmitted to humans from non-  
300 human sources or, (b) human diseases causes by organisms that may acquire resistance  
301 genes from non-human sources). Hence, the increasing of antimicrobial resistance in  
302 general and resistance to these antibiotics in particular, may represent a major threat to  
303 human health (EU Commission, 2010).

304 To conclude, in this work we have demonstrated the existence of a high percentage  
305 of resistant *E. coli* strains in one old day chickens, not exposed previously to any  
306 antibiotic, what strongly suggest the possibility of vertical transmission from parenteral  
307 flocks. On the other hand, influence of amoxicillin treatments in increasing resistances  
308 to beta-lactams, aminoglycosides and cloramphenicol has been shown. Critical  
309 importance to human health of the antimicrobial resistances found highlights the  
310 importance to take immediately control measures focusing on reducing vertical and  
311 horizontal transmission in farm environment.

312 Conflict of interest

313 None to declare

### 314 **Acknowledgments**

315 The authors would like to thank the CITA-IVIA for the provision of one day  
316 chickens and his technical support.

317

### 318 **References**

- 319 Apajalahti, J., Kettunen, A., & Graham, H. (2004). Characteristics of the gastrointestinal microbial  
320 communities, with special reference to chicken. *World's Poultry Science Journal*, 60, 223–232.
- 321 Baron S., Jouy E., Larvor E., Eono F, Bougeard S. & Kempf I. (2014). Impact of Third-Generation  
322 Cephalosporin Administration in Hatcheries on Fecal Escherichia coli Antimicrobial Resistance in  
323 Broilers and Layers. *Antimicrobial Agents and Chemotherapy*, 58, 5428–5434.
- 324 Bywater, R., Deluyker, H., Deroover, E., Jong, A., Marion, H., McConville, M., Rowan, T., Shryock, T.,  
325 Shuster, D., Thomas, V., Valle M., & J. Walters. (2004). A European survey of antimicrobial  
326 susceptibility among zoonotic and commensal bacteria isolated from food-producing animals.  
327 *Journal of Antimicrobial Chemotherapy*, 54, 744–754.
- 328 Binnewies, T.T., Motro, Y., Hallin, P.F., Lund, O., Dunn, D., La, T., Hampson, D.J., Bellgard, M.,  
329 Wassenaar, T.M. & Ussery, D.W. (2006). Ten years of bacterial genome sequencing: comparative-  
330 genomics-based discoveries. *Functional & Integrative Genomics*, 6, 165–185.

331 Bortolaia, V., Bisgaard, M., & Bojesen, A. M. (2010). Distribution and possible transmission of  
332 ampicillin- and nalidixic acid-resistant *Escherichia coli* within the broiler industry. *Veterinary*  
333 *Microbiology*, 142, 379-386.

334 Chen, X., Zhang, W., Yin, J., Zhang, N., Geng, S., Zhou, X., Wang, Y., Gao, S., & Jiao, X., (2014).  
335 *Escherichia coli* isolates from sick chickens in China: changes in antimicrobial resistance between  
336 1993 and 2013. *Veterinary Journal*, 202, 112-5.

337 Dierikx, C.M., Van der Goot, J.A., Smith, H.E., Kant, A., & Mevius D.J., (2013). Presence of  
338 ESBL/AmpC-producing *Escherichia coli* in the broiler production pyramid: a descriptive study.  
339 PLoS One 8:e79005. <http://dx.doi.org/10.1371/journal.pone.0079005>  
340 (Accessed September 2015).

341 Doménech, E., Jimenez-Belenguer, A., Perez, R., Ferrus, M.A., & Escriche, I. (2015). Risk  
342 characterization of antimicrobial resistance of *Salmonella* in meat products. *Food Control*. 57, 18-  
343 23.

344 EFSA 2013 The European Union Summary Report on antimicrobial resistance in zoonotic and indicator  
345 bacteria from humans, animals and food in 2011. *EFSA Journal*, 11, 3196  
346 [http://www.efsa.europa.eu/sites/default/files/scientific\\_output/files/main\\_documents/3196.pdf](http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/3196.pdf)  
347 (Accessed October 2015).

348 EU commission 2010 Progress report on the Action plan against the rising threats from Antimicrobial  
349 Resistance Brussels, 11.3.2015 SWD(2015) 59 final.  
350 [http://ec.europa.eu/health/antimicrobial\\_resistance/docs/2015\\_amr\\_progress\\_report\\_en.pdf](http://ec.europa.eu/health/antimicrobial_resistance/docs/2015_amr_progress_report_en.pdf)  
351 (Accessed September 2015).

352 EU Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the  
353 protection of animals used for scientific purposes Text with EEA relevance  
354 <http://eurlex.europa.eu/legalcontent/ES/TXT/PDF/?uri=CELEX:32010L0063&from=EN>  
355 (Accessed November 2015).

356 FAO 2010. Agribusiness handbook Poultry Meat & Eggs.  
357 [http://www.eastagri.org/publications/pub\\_docs/6\\_Poultry\\_web.pdf](http://www.eastagri.org/publications/pub_docs/6_Poultry_web.pdf)  
358 (Accessed September 2015).



359 Furtula, V., Farrell, E.G., Diarrassouba, F., Rempel, H., Pritchard, J., & Diarra, M.S., (2010). Veterinary  
360 pharmaceuticals and antibiotic resistance of *Escherichia coli* isolates in poultry litter from  
361 commercial farms and controlled feeding trials. *Poultry. Science*, 89, 180–188.

362 Giovanardi, D., Campagnari, E., Ruffoni, L.S., Pesente, P., Ortali, G., & Furlattini, V. (2005). Avian  
363 pathogenic *Escherichia coli* transmission from broiler breeders to their progeny in an integrated  
364 poultry production chain. *Avian Pathology*. 34, 313–318.  
365 <http://dx.doi.org/10.1080/03079450500179046> (Accessed September 2015).

366 Greenacre, M. ,2007. Correspondence Analysis in Practice. (Second Edition). London: Chapman & Hall /  
367 CRC Press.

368 Martins da Costa, P., Belo, A.; Gonçalves, J., & Bernardo, F. (2009). Field trial evaluating changes in  
369 prevalence and patterns of antimicrobial resistance among *Escherichia coli* and *Enterococcus* spp.  
370 isolated from growing broilers medicated with enrofloxacin, apramycin and amoxicillin.  
371 *Veterinary Microbiology*, 139, 284–292.

372 McEwen, S. A., & Fedorka-Cray, P. J. (2002). Antimicrobial Use and Resistance in Animals. *Clinical*  
373 *Infectious Diseases*, 34, S93–106.

374 Miller, C., Thomsen, L.E., Gaggero, C., Mosseri, R., Ingmer, H., Cohen, S.N., (2004). SOS response  
375 induction by beta-lactams and bacterial defense against antibiotic lethality. *Science*, 305, 1629–  
376 1631.

377 Miranda, J. M., Vázquez, B. I., Fente, C. A., Barros-Velázquez, J., Cepeda, A., & Franco, C. M.  
378 (2008). Evolution of Resistance in Poultry Intestinal *Escherichia coli* During Three Commonly  
379 Used Antimicrobial Therapeutic Treatments in Poultry. *Poultry Science*, 87, 1643–1648.  
380 doi:10.3382/ps.2007-00485

381 Nordstrom, K., (2005). Plasmid R1 – replication and its control. *Plasmid*, 55, 1–26.

382 Petersen, A., Christensen, J.P., Kuhnert, P., Bisgaard, M., & Olsen, J.E. (2006). Vertical transmission of a  
383 fluoroquinolone-resistant *Escherichia coli* within an integrated broiler operation. *Veterinary*  
384 *Microbiology*, 116, 120–128.

385 Phillips, I., Casewell, M., Cox, T., De Groot, B., Friis, C., Jones, R., Nightingale, C., Preston, R., &  
386 Waddell, J. (2003). Does the use of antibiotics in food animals pose a risk to human health? A  
387 critical review of published data. *Journal of Antimicrobial Chemotherapy*, 53:28–52.

388 Regulation 1831/2003/EC on additives for use in animal nutrition, replacing Directive 70/524/EEC on  
389 additives in feeding-stuffs. [http://eur-lex.europa.eu/legal-](http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32003R1831)  
390 [content/EN/TXT/?uri=CELEX:32003R1831](http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32003R1831) (Accessed November 2015).

391 Sáenz, Y., Zarazaga, M., Briñas, L., Lantero, M., Ruiz-Larrea, F., & Torres, C. (2001). Antibiotic  
392 resistance in *Escherichia coli* isolates obtained from animals, foods and humans in Spain.  
393 *International Journal of Antimicrobial Agents*, 18, 353-358.

394 Smith, J. L., Drum, D. J. V., Dai, Y., Kim, J. M., Sanchez, S., Maurer, J. J., Hofacre C. L., & Lee, M. D.  
395 (2007). Impact of antimicrobial usage on antimicrobial resistance in commensal *Escherichia coli*  
396 strains colonizing broiler chickens. *Applied and Environmental Microbiology*, 73, 1404-1414.

397 Van den Bogaard, A.E., London, N., Driessen, C., & Stobberingh, E.E. (2001). Antibiotic resistance of  
398 faecal *Escherichia coli* in poultry, poultry farmers and poultry slaughterers. *Journal of*  
399 *Antimicrobial Chemotherapy*, 47, 763-771.

400 Watson, R. (2008). Multidrug resistance responsible for half of deaths from healthcare associated  
401 infections in Europe. *British Medical Journal*, 336, 1266-1267.

402 WHO. 2012. Critically important antimicrobials for human medicine. World Health Organization, 3<sup>rd</sup>  
403 Revision 2011 [http://apps.who.int/iris/bitstream/10665/77376/1/9789241504485\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/77376/1/9789241504485_eng.pdf)  
404 (Accessed September 2015).

405

406 Figure captions

407

408 Figure 1. Percentage of *E. coli* resistant (■), intermediate (▒) and sensitive  
409 (□) in meconia of day-old chicks. Where AK= Amikacin; AMC= Amoxicilin/  
410 clavulamic acid; AMP=Ampicillin; C= Chloramphenicol; CIP= Ciprofloxacin; CN=  
411 Gentamicin; CRO= Ceftriaxone; K= Kanamycin; KF= Cephalothin; NA= Nalidixic  
412 acid; TE= Tetracycline; S= Streptomycin

413

414 Figure 2. MCA bi-plot. Antibiotics tested: A. AMP =Ampicillin; A. C =  
415 Chloramphenicol; A. CN = Gentamicin; A. CRO = Ceftriaxone; A. K= kanamycin; A.  
416 NA = Nalidixic acid; A. SXT = Trimethoprim/sulphametoxazol; A. TE = Tetracycline.  
417 Before any dose administrations (C0), after the three dose administrations (T1, T2 and  
418 T3), and the same sampling for the control group (C1, C2, C3). VR = (resistant), VI =  
419 (intermediate), VS = (sensitive).

420

421 Figure 3: Percentage of *E. coli* resistant (■), intermediate (▒) and sensitive (□) for  
422 the group of control (C1, C2, and C3) and after the three treatments (T1, T2 and T3).  
423 Where AK= Amikacin; AMC= Amoxicilin/ clavulamic acid; AMP=Ampicillin; C=  
424 Chloramphenicol; CIP= Ciprofloxacin; CN= Gentamicin; CRO= Ceftriaxone; K=  
425 Kanamycin; KF= Cephalothin; NA= Nalidixic acid; TE= Tetracycline; S= Streptomycin

426